Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-28T05:51:28.313Z Has data issue: false hasContentIssue false

3 - Principles of Chemotherapy

from PART I - PRINCIPLES OF ONCOLOGY

Published online by Cambridge University Press:  18 May 2010

By
Rowena Schwartz ,
Tiffany V. Goolsby  and
Wells A. Messersmith
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Rowena Schwartz
Affiliation:
Director of Oncology Pharmacy, Johns Hopkins University School of Medicine, Baltimore, MD
Tiffany V. Goolsby
Affiliation:
Clinical Pharmacist, Johns Hopkins Pharmacy, Baltimore, MD
Wells A. Messersmith
Affiliation:
Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

ANTI-NEOPLASTIC AGENTS

The pharmacological approach to chemotherapy encompasses a wide number and many types of medications. Classically, cytotoxic agents that target rapidly dividing cancer cells have been the mainstay of treatment. More recently, the use of agents that target the immune system (immunotherapy), the biological pathways of malignant cells (targeted therapy) and the hormonal environment of the cancer (endocrine therapy) have been developed to use as single agents and in combination with other anti-neoplastic agents. This chapter overviews the common classes of antineoplastic agents and discusses some of the most common related toxicities. A more extensive review of these agents is available in many texts (1–3) and in published reviews. A quick reference list of toxicities for specific agents is available (4) and delineates between acute and delayed toxicities.

Agents used as cancer therapy are commonly categorized by mechanism (e.g., anti-metabolite or tyrosine kinase inhibitor) or origin (e.g., vinca alkaloid). Within a specific class of agents, the drugs differ significantly in pharmacology, activity and clinical application. Toxicities are often unique to an agent within a class, and the manifestation of a drug-induced side effect may vary significantly based on the drug dose, schedule, route of administration and drug therapy combination. Additionally, the tolerability of most drugs used in the treatment of cancer depends upon numerous aspects of an individual. Factors such as disease, organ function (e.g., renal function, liver function), comorbidities and concomitant medications impact toxicities and pharmacology of many agents.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 28 - 37
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abeloff, M D, Armitage, J O, Niederhuber, J E. Clinical Oncology, 3rd edition. Philadelphia: Elsevier Churchill Livingstone 2004.Google Scholar
Devita, V T, Hellman, S, Rosenberg, S A, eds. Cancer: Principles and Practices of Oncology, 7th edition. Philadelphia: Lippincott-Raven 2005.Google Scholar
Chabner, B A, Longo, D L, eds. Cancer Chemotherapy and Biotherapy: Principles and Practices, 3rd edition. Philadelphia: Lippincott Williams & Wilkins 2001.Google Scholar
Drugs of Choice for Cancer. Treatment Guidelines from the Medical Letter. 2003;1:41–52.
McGuire, J J. Anticancer antifolates: Current status and future directions. Curr Pharm Des 2003;9:2593–2613.CrossRefGoogle ScholarPubMed
Nagle, A, Hur, W, Gray, N S. Antimitotic agents of natural origin. Curr Drug Targets 2006;7:305–326.CrossRefGoogle ScholarPubMed
Kiselyov, A, Balakin, K V, Tkachenko, S E. Recent progress in discovery and development of antimitotic agents. Anticancer Agents Med Chem 2007;7:189–208.CrossRefGoogle ScholarPubMed
Kingston, D G, Newman, D J. Taxoids: Cancer-fighting compounds from nature. Curr Opin Drug Discov Devel 2007 Mar;10:130–144.Google ScholarPubMed
Socinski, M. Update on nanoparticle albumin-bound paclitaxel. Clin Adv Hematol Oncol [review] 2006 Oct;4(10):745–746.Google ScholarPubMed
Pommier, Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006;6:789–802.CrossRefGoogle ScholarPubMed
Musa, M A, Khan, M O, Cooperwood, J S. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators. Curr Med Chem 2007;14:1249–1261.CrossRefGoogle ScholarPubMed
Toi, M, Bando, H, Saji, S. Aromatase and aromatase inhibitors. Breast Cancer 2001;8:329–332.CrossRefGoogle ScholarPubMed
Moreau, J P, Delavult, P, Blumberg, J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. Clin Ther 2006;28:1485–1508.CrossRefGoogle ScholarPubMed
Debruyne, F, Bhat, G, Garnick, M B. Abarelix for injectable suspension: First-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006;2:677–696.CrossRefGoogle ScholarPubMed
Wirth, M P, Hakenberg, O W, Froehner, M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51:306–313.CrossRefGoogle ScholarPubMed
Madhusudan, S, Ganesan, T S. Tyrosine kinase inhibitors and cancer therapy. Recent Result Cancer Res 2007;172:25–44.CrossRefGoogle ScholarPubMed
Ferrantini, M, Capone, I, Belardelli, F. Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 2007 Jun-Jul;89:884–893.CrossRefGoogle ScholarPubMed
Atkins, M B. Interleukin-2: Clinical applications. Semin Oncol 2002;29(Suppl 7):12–17.CrossRefGoogle ScholarPubMed
Khandare, J J, Minko, T. Antibodies and peptides in cancer therapy. Crit Rev Ther Drug Carrier Syst 2006;23:401–435.Google ScholarPubMed
Boerman, O C, Koppe, M J, Postema, E J. Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents Med Chem 2007;7:335–343.Google ScholarPubMed
Raje, N, Hideshima, T, Anderson, K C. Therapeutics uses of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2006;6:1239–1247.CrossRefGoogle Scholar
Zavrski, I, Jakob, C, Kaiser, M. Molecular and clinical aspects of proteosome inhibition in treatment of cancer. Recent Result Cancer Res 2007;176:165–176.CrossRefGoogle Scholar
Brueckner, B, Kuck, D, Lyko, E. DNA methyltransferase inhibitors for cancer treatment. Cancer J 2007; 13: 17–22.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Principles of Chemotherapy
    • By Rowena Schwartz, Director of Oncology Pharmacy, Johns Hopkins University School of Medicine, Baltimore, MD, Tiffany V. Goolsby, Clinical Pharmacist, Johns Hopkins Pharmacy, Baltimore, MD, Wells A. Messersmith, Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.004
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Principles of Chemotherapy
    • By Rowena Schwartz, Director of Oncology Pharmacy, Johns Hopkins University School of Medicine, Baltimore, MD, Tiffany V. Goolsby, Clinical Pharmacist, Johns Hopkins Pharmacy, Baltimore, MD, Wells A. Messersmith, Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.004
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Principles of Chemotherapy
    • By Rowena Schwartz, Director of Oncology Pharmacy, Johns Hopkins University School of Medicine, Baltimore, MD, Tiffany V. Goolsby, Clinical Pharmacist, Johns Hopkins Pharmacy, Baltimore, MD, Wells A. Messersmith, Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
  • Edited by Jean-François H. Geschwind, The Johns Hopkins University School of Medicine, Michael C. Soulen, University of Pennsylvania School of Medicine
  • Book: Interventional Oncology
  • Online publication: 18 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511722226.004
Available formats
×